Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Thrombocytopenia Stories

2013-06-27 23:29:59

Conquer Low Platelets created by Louis Cruz is a new book that teaches people how to increase platelets by using proven and natural remedies. In a full Conquer Low Platelets overview, Tony Nguyen from the site Vkool.com indicates if the book is worth buying. Seattle, Wa (PRWEB) June 27, 2013 Conquer Low Platelets created by Louis Cruz is a new book that teaches people how to increase platelets naturally and quickly by using natural remedies. This book also instructs people how to avoid...

2013-06-17 04:22:47

- Pooled Analysis from Four Phase 1 and Phase 2 Clinical Studies Demonstrates Persistence of Treatment - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1...

2013-05-09 23:52:04

http://www.DrugRisks.com is the most useful source on the web for prescription medication alerts, side effects and legal news. Visit us today. Chicago, IL (PRWEB) May 08, 2013 The medication resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. The maker of the drug recently updated label warnings to include the risk of a blood platelet disorder*. DrugRisks was created to improve the safety of patients taking popular...

2013-02-21 08:34:03

KING OF PRUSSIA, Pa., Feb. 21, 2013 /PRNewswire/ -- CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen®, immune globulin intravenous [human]. The new vial size will simplify preparation and administration of the product when high volumes of it are required. Privigen is approved for the treatment of patients with primary immunodeficiency (PID), a group of rare and serious diseases of the immune system, and...

2013-01-09 04:20:57

SEATTLE, Jan. 9, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis. The randomized trial is expected to enroll 270 patients and will evaluate the safety and efficacy of pacritinib compared...

2012-12-05 16:24:35

THOUSAND OAKS, Calif., Dec. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology (ASH) from Dec. 8-11, 2012, in Atlanta. These include updated results from a Phase 2 trial evaluating blinatumomab in B-precursor acute lymphoblastic leukemia (ALL) and data evaluating long-term use of Nplate(®) (romiplostim) in pediatric chronic immune thrombocytopenia (ITP). "The research...

2012-11-20 13:40:37

May provide treatment option for those with harder-to-treat memory problems, skin ulcers and kidney disease Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal...

2012-11-19 08:28:59

LONDON, Nov. 19, 2012 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood...

2012-07-25 02:31:24

SOUTH SAN FRANCISCO, Calif., July 25, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Blood, the medical journal of the American Society of Hematology, has published results from the 003-A1 Phase 2b trial, a single-arm, multicenter clinical trial evaluating Kyprolis(TM) (carfilzomib) for Injection for the treatment of patients with advanced multiple myeloma, who had received a median of five prior anti-myeloma regimens. The lead author was Dr. David Siegel,...

2012-07-05 10:22:42

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options....